Role of Lung Surfactant in Phagocytic Clearance of Apoptotic Cells by Macrophages in Rats

Details

• Personal Author:
  Antonini JM ; Castranova, Vincent ; Mercer RR ; Roberts, Jennifer R. ; Rojanasakul Y ; Scabilloni JF ; Wang LY ; Zhang Z
• Description:
  Two of the common features of inflammatory lung diseases are the increased production of pulmonary surfactant and the induction of lung cell apoptosis. However, the relationship between these two events has not been addressed. To investigate the role of surfactant in pulmonary inflammation and apoptosis, we instilled natural lung surfactant (Survanta) (1.6-12.5 mg) into the rat lungs and determined the number of alveolar macrophages (AMs) and apoptotic lung cells. High-dose treatments of Survanta (>6.25 mg/rat) caused an increase in macrophage cell influx and lung cell apoptosis at 4 weeks post-treatment. In vitro studies using lavaged macrophages showed Survanta did not cause apoptosis. We then examined the role of Survanta on ability of macrophages phagocytizing apoptotic cells. This study demonstrated that macrophages were able to eliminate apoptotic cells more efficiently in the absence of surfactant than in its presence. In vivo, high doses of Survanta decreased the ability to clear exogenously instilled apoptotic cells or bacteria. Taken together, our results suggest that excessive accumulation of lung surfactant by Survanta treatment can impair or overwhelm the phagocytic clearance function of AMs and that this impairment may lead to increased presence of apoptotic cells in the lung and bacterial survival.Laboratory Investigation (2006) 86, 458-466. [Description provided by NIOSH]
• Subjects:
  Animals Laboratories Lung Diseases Occupational Health Respiratory Tract Diseases Safety Surface-Active Agents
• Keywords:
  Animal-studies Diseases In-vitro-studies In-vivo-studies Laboratory-animals Lung-disease Lung-disorders Phagocytes Pulmonary-system-disorders Surfactants
• ISSN:
  0023-6837
• Document Type:
  Text
• Genre:
  Journal Article
• Place as Subject:
  OSHA Region 3 ; West Virginia
• CIO:
  National Institute for Occupational Safety and Health (NIOSH)
• Division:
  HELD - Health Effects Laboratory Division
• Topic:
  Workplace Safety & Health
• Location:
  North America
• Pages in Document:
  458-466
• Volume:
  86
• Issue:
  5
• NIOSHTIC Number:
  nn:20030157
• Citation:
  Lab Invest 2006 May; 86(5):458-466
• Contact Point Address:
  Dr L Wang, MD, PhD, Pathology and Physiology Research Branch, National Institute for Occupational Safety and Health, 1095 Willowdale Road, Morgantown, WV 26505, USA
• Email:
  lmw6@cdc.gov
• Federal Fiscal Year:
  2006
• NORA Priority Area:
  Work Environment and Workforce: Emerging Technologies
• Peer Reviewed:
  True
• Source Full Name:
  Laboratory Investigation
• Collection(s):
  National Institute for Occupational Safety and Health
• Main Document Checksum:
  urn:sha-512:1dd48d1a8152e6426ec81f61aef0d3dc210d2e5b0fb0518eb0e265bafee4b00a51ed6ffbabda973025df92bd4cffddae654447701df1f1eae76ae4359726fef5
• Download URL:
  https://stacks.cdc.gov/view/cdc/190958/cdc_190958_DS1.pdf
• File Type:
  [PDF - 488.75 KB ]